A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
Status:
Recruiting
Trial end date:
2022-05-10
Target enrollment:
Participant gender:
Summary
This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety,
tolerability, PK, PD, and clinical activity of domvanalimab (AB154) as monotherapy and in
combination with zimberelimab (AB122) in participants with advanced solid malignancies.